Semaglutide, an FDA-approved drug used to treat type 2 diabetes and obesity, has shown potential to reduce alcohol consumption and addictive behaviors such as the craving for drugs and alcohol. Preclinical studies on rodents and monkeys have demonstrated that semaglutide can reduce the consumption of food and addictive substances like alcohol, nicotine, cocaine, and amphetamines. Recent human studies have shown that semaglutide can reduce symptoms of alcohol use disorder, indicating its potential as a treatment for addiction. Clinical trials are currently underway to further explore semaglutide’s effectiveness in treating alcohol use disorder, with results expected in the next 1-2 years.
Source link
How an Obesity Drug Could Help Alcohol Use Disorder
